Coya’s combination drug shows promise against neuroinflammation in mouse study
Coya Therapeutics has published preclinical results for COYA 303 in the International Journal of Molecular Sciences. COYA 303 is a combination of proprietary low-dose interleukin-2 and a glucagon-like peptide 1 receptor agonist that the company says was evaluated in a subacute low-dose lipopolysacch
<p>Coya Therapeutics has published preclinical results for COYA 303 in the International Journal of Molecular Sciences. COYA 303 is a combination of proprietary low-dose interleukin-2 and a glucagon-like peptide 1 receptor agonist that the company says was evaluated in a subacute low-dose lipopolysacch</p>